72 related articles for article (PubMed ID: 25397538)
1. Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity.
Patterson P; Socías E; Pryluka D; Lapadula P; Pérez H; Cahn P
J Int AIDS Soc; 2014; 17(4 Suppl 3):19794. PubMed ID: 25397538
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
[TBL] [Abstract][Full Text] [Related]
3. Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
Pinnetti C; Di Giambenedetto S; Maggiolo F; Lorenzini P; Fabbiani M; Tommasi C; Latini A; Ammassari A; Loiacono L; Sterrantino G; Bellagamba R; Boumis E; Antinori A; Zaccarelli M
J Int AIDS Soc; 2014; 17(4 Suppl 3):19812. PubMed ID: 25397556
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chaovavanich A
J Med Assoc Thai; 2008 Feb; 91(2):159-65. PubMed ID: 18389979
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Inthong Y; Prasithsirikul W; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chumpathat N; Termvises P; Chaovavanich A
Int J STD AIDS; 2007 Nov; 18(11):782-6. PubMed ID: 18005514
[TBL] [Abstract][Full Text] [Related]
6. Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to CD4 cell counts: results of the TOSCANA study.
Antela A; Ocampo A; Gómez R; López MJ; Mariño A; Losada E; Rodríguez R; Fernández R; Corredoira JC; Naval G; Rodríguez A; Miralles C; Prieto A; Gevihga Galician HIV Study Group
HIV Clin Trials; 2010; 11(1):11-7. PubMed ID: 20400407
[TBL] [Abstract][Full Text] [Related]
7. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients.
Podzamczer D; Rojas JF; Neves I; Ferrer E; Llibre JM; Leal M; Gorgolas M; Jose CM; Gatell JM; Abreu RC; Curto J; Domingo P; Pilar BM; Rozas N
J Int AIDS Soc; 2014; 17(4 Suppl 3):19773. PubMed ID: 25397517
[TBL] [Abstract][Full Text] [Related]
9. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.
Ena J; Leach A; Nguyen P
HIV Med; 2008 Oct; 9(9):747-56. PubMed ID: 18651856
[TBL] [Abstract][Full Text] [Related]
10. Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly.
Sanjeeva GN; Sukanya V; Pavithra HB; Dodderi SK; Rewari BB; Govindaraj M; Shivananda S; Premalatha R
AIDS Care; 2015; 27(5):655-9. PubMed ID: 25517472
[TBL] [Abstract][Full Text] [Related]
11. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
[TBL] [Abstract][Full Text] [Related]
12. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
14. Successful viral suppression with subsequent efavirenz-based regimen in HIV-1-infected patients who stop nevirapine prior to discontinuation of the NRTI backbone.
Chimsuntorn S; Sungkanuparph S; Manosuthi W
J Int Assoc Physicians AIDS Care (Chic); 2010; 9(1):43-5. PubMed ID: 20071597
[TBL] [Abstract][Full Text] [Related]
15. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
16. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
17. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
[TBL] [Abstract][Full Text] [Related]
18. Risk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell count.
Knobel H; Guelar A; Montero M; Carmona A; Luque S; Berenguer N; González A
HIV Med; 2008 Jan; 9(1):14-8. PubMed ID: 18199168
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.
Kesselring AM; Wit FW; Sabin CA; Lundgren JD; Gill MJ; Gatell JM; Rauch A; Montaner JS; de Wolf F; Reiss P; Mocroft A;
AIDS; 2009 Aug; 23(13):1689-99. PubMed ID: 19487907
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
